Drug Profile
Research programme: transcription factor LSF inhibitors - PharmLogic/Boston University
Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Boston University
- Developer Boston University; PharmLogic
- Class Small molecules
- Mechanism of Action Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for research development in liver cancer in USA